Davide Corti

Summary

Publications

  1. doi request reprint Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease
    Davide Corti
    Humabs BioMed SA, 6500 Bellinzona, Switzerland Electronic address
    Curr Opin Immunol 40:51-61. 2016
  2. doi request reprint Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome
    Davide Corti
    Humabs BioMed SA, 6500 Bellinzona, Switzerland Electronic address
    J Infect Public Health 9:231-5. 2016
  3. doi request reprint Cross-neutralization of four paramyxoviruses by a human monoclonal antibody
    Davide Corti
    Humabs BioMed SA, Via Mirasole 1, 6500 Bellinzona, Switzerland
    Nature 501:439-43. 2013
  4. pmc The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies
    Maria J Duenas-Decamp
    Center for AIDS Research, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, MA 01605, USA
    Retrovirology 9:9. 2012
  5. doi request reprint A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins
    Davide Corti
    Institute for Research in Biomedicine, 6500 Bellinzona, Switzerland
    Science 333:850-6. 2011
  6. pmc Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer
    Anna Kabanova
    Institute for Research in Biomedicine, University of Italian Switzerland, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
    Nat Microbiol 1:16082. 2016
  7. pmc Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
    Davide Corti
    Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland Humabs BioMed SA, 6500 Bellinzona, Switzerland
    Proc Natl Acad Sci U S A 112:10473-8. 2015
  8. doi request reprint Antibody-guided vaccine design: identification of protective epitopes
    Antonio Lanzavecchia
    Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland Institute of Microbiology, ETH Zurich, Vladimir Prelog Weg 1, 8093 Zurich, Switzerland Electronic address
    Curr Opin Immunol 41:62-7. 2016
  9. doi request reprint Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection
    Karin Stettler
    Humabs BioMed SA, Via Mirasole 1, 6500 Bellinzona, Switzerland
    Science 353:823-6. 2016
  10. pmc A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens
    Joshua Tan
    Institute for Research in Biomedicine, Università della Svizzera italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
    Nature 529:105-9. 2016

Collaborators

  • Maria Zambon
  • Fausto Baldanti
  • Peter D Kwong
  • Stanley Perlman
  • Giuseppe Gerna
  • Benjamin J Marsland
  • Nigel Temperton
  • Cameron P Simmons
  • Philip Bejon
  • Antonio Lanzavecchia
  • Federica Sallusto
  • Mathilde Foglierini
  • Anna Kabanova
  • Siro Bianchi
  • Laurent Perez
  • Roger Geiger
  • Joshua Tan
  • Karin Stettler
  • Daniele Lilleri
  • Blanca Fernandez-Rodriguez
  • Jessica Marcandalli
  • Luca Piccoli
  • Elena Percivalle
  • Gloria Agatic
  • Leontios Pappas
  • Maria J Duenas-Decamp
  • Johannes Blum
  • Yaroslav Tsybovsky
  • Eva Harris
  • Baoshan Zhang
  • Abdirahman Abdi
  • Chiara Silacci Fregni
  • Luca Varani
  • Juliana Wambua
  • Antonino Cassotta
  • Andrea Minola
  • Chiara Silacci-Fregni
  • Claire Maria Tully
  • Roger Hewson
  • Stefano Jaconi
  • Victoria Graham
  • Kevin Marsh
  • Luca Simonelli
  • Blanca Maria Fernandez-Rodriguez
  • Peter Bull
  • Vandana Thathy
  • Mattia Pedotti
  • Diego A Espinosa
  • Tongqing Zhou
  • Kathrin Pieper
  • Francis Maina Ndungu
  • Fabrizia Vanzetta
  • Federico Mele
  • Martina Beltramello
  • Aliaksandr Druz
  • Alexander Frühwirth
  • Elisabetta Cameroni
  • Sonia Barbieri
  • David Jarrossay
  • Ulrich Baxa
  • Massimiliano Pagani
  • Stuart Dowall
  • Barry Atkinson
  • Elisa Vicenzi
  • Filippo Turrini
  • Gabriele Pellicciotta
  • Chiara Silacci
  • Simone Becattini
  • Qing Zhu
  • Silvia Preite
  • Nicole L Kallewaard
  • Isabella Giacchetto-Sasselli
  • Dario Fuschillo
  • Olivia J O'Connell
  • Paul R Clapham
  • Susan Zolla-Pazner

Detail Information

Publications13

  1. doi request reprint Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease
    Davide Corti
    Humabs BioMed SA, 6500 Bellinzona, Switzerland Electronic address
    Curr Opin Immunol 40:51-61. 2016
    ..Here, we will provide historical context on the use of oligoclonal antibodies in oncology and infectious diseases and will highlight practical considerations related to their preclinical and clinical development programs. ..
  2. doi request reprint Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome
    Davide Corti
    Humabs BioMed SA, 6500 Bellinzona, Switzerland Electronic address
    J Infect Public Health 9:231-5. 2016
    ..Currently, the LCA60 antibody is being considered for clinical development, which includes prophylaxis in individuals at risk and a treatment for severe MERS-CoV infections. ..
  3. doi request reprint Cross-neutralization of four paramyxoviruses by a human monoclonal antibody
    Davide Corti
    Humabs BioMed SA, Via Mirasole 1, 6500 Bellinzona, Switzerland
    Nature 501:439-43. 2013
    ..Taken together, these results indicate that MPE8 might be used for the prophylaxis and therapy of severe HRSV and HMPV infections and identify the pre-fusion F protein as a candidate HRSV vaccine. ..
  4. pmc The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies
    Maria J Duenas-Decamp
    Center for AIDS Research, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, MA 01605, USA
    Retrovirology 9:9. 2012
    ..We compared HIV-1 envelopes and corresponding mutants that carried blocked W100 pockets to evaluate whether other CD4bs mabs target this site...
  5. doi request reprint A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins
    Davide Corti
    Institute for Research in Biomedicine, 6500 Bellinzona, Switzerland
    Science 333:850-6. 2011
    ..This antibody may be used for passive protection and to inform vaccine design because of its broad specificity and neutralization potency...
  6. pmc Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer
    Anna Kabanova
    Institute for Research in Biomedicine, University of Italian Switzerland, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
    Nat Microbiol 1:16082. 2016
    ..These findings help explain the broad tropism of human cytomegalovirus and indicate that PDGFRα and the viral gO subunit could be targeted by novel anti-viral therapies...
  7. pmc Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
    Davide Corti
    Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland Humabs BioMed SA, 6500 Bellinzona, Switzerland
    Proc Natl Acad Sci U S A 112:10473-8. 2015
    ....
  8. doi request reprint Antibody-guided vaccine design: identification of protective epitopes
    Antonio Lanzavecchia
    Institute for Research in Biomedicine, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland Institute of Microbiology, ETH Zurich, Vladimir Prelog Weg 1, 8093 Zurich, Switzerland Electronic address
    Curr Opin Immunol 41:62-7. 2016
    ..We will also discuss how the genealogical analysis of antigen-stimulated B cell clones provides the basis to delineate the best suitable prime-boost vaccination strategy for the induction of broadly neutralizing antibodies. ..
  9. doi request reprint Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection
    Karin Stettler
    Humabs BioMed SA, Via Mirasole 1, 6500 Bellinzona, Switzerland
    Science 353:823-6. 2016
    ..An EDIII-specific antibody protected mice from lethal ZIKV infection, illustrating the potential for antibody-based therapy. ..
  10. pmc A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens
    Joshua Tan
    Institute for Research in Biomedicine, Università della Svizzera italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
    Nature 529:105-9. 2016
    ....
  11. pmc Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies
    Anna Kabanova
    Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland
    Proc Natl Acad Sci U S A 111:17965-70. 2014
    ..These results illustrate with a relevant example a general and practical approach of analytic vaccinology for the development of subunit vaccines against complex pathogens. ..
  12. doi request reprint Broadly neutralizing antiviral antibodies
    Davide Corti
    Institute for Research in Biomedicine IRB, 6500 Bellinzona, Switzerland
    Annu Rev Immunol 31:705-42. 2013
    ..These antibodies not only provide new tools for prophylaxis and therapy for viral diseases but also identify conserved epitopes that may be used to design new vaccines capable of conferring broader protection...
  13. doi request reprint Rapid development of broadly influenza neutralizing antibodies through redundant mutations
    Leontios Pappas
    Insitute for Research in Biomedicine, Università della Svizzera italiana, Via Vincenzo Vela 6, 6500 Bellinzona, Switzerland
    Nature 516:418-22. 2014
    ....